Crucial Considerations in Monitoring Process Performance and Product Quality - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Crucial Considerations in Monitoring Process Performance and Product Quality
The author outlines key considerations for carrying out a structured approach to monitoring process performance and ensuring product quality.


Pharmaceutical Technology
Volume 34, pp. S38-S42


Figure 3: Control chart showing batch tablet weight produced using two presses (A and B). UCL is upper control limit and LCL is lower control limit.
Figure 3 shows a control chart for a total weight of 10 tablets manufactured by two tablet presses. The graphic demonstrates that both presses are stable and in control and producing tablets with the same average weight and variation.


Figure 4: Control chart showing assay values of batches produced over three years. UCL is upper control limit and LCL is lower control limit.
Figure 4 shows a control chart for assay values for batches produced over a 3-year period. The process is stable through the middle of Year 2 and begins to decrease in Year 3. When a process adjustment is made, the batch assay values return close to the values observed in Year 1. This example is interesting because a process shift is shown, but none of the batch assay values are close to the assay specifications of 90–110%.

Out-of-specification (OOS) and out-of-control (OOC) values require investigation. These values are not always caused by manufacturing problems, and may be caused by sampling errors, testing errors, or human administration errors such as recording or data keying. The causes of OOS and OOC measurements should be carefully considered when interpreting the OOC and OOS values and deciding on appropriate action.




Process-capability analysis. A process-capability analysis is conducted to determine the ability of the process to meet product specifications. The Ppk value represents the ratio of the difference between the process average and the nearest specification divided by three times the process SD (see Equation 2).


Table I: Summary of process performance index (Ppk value) interpretation.
Where A is the upper specification minus the process average and B is the process average minus the lower specification. Two main statistics are used to measure process capability: percent of the measurements OOS and the process Ppk value. The interpretation of the Ppk value is summarized in Table I.


Figure 5: Process capability for a tablet weight of Ppk = 1.91. LSL is lower specification limit and USL is upper specification limit.
Process capability indices of Ppk of 2.0 and higher are consistent with high-performance processes or robust processes. Figure 4 shows an example of process capability for tablet weight. In this case, the Ppk value is 1.91 (an excellent category) which is based on the distribution of tablet weights being a considerable distance from the lower and upper specifications for tablet weight.

When a process is robust, small process upsets will not create OOS product. Accordingly, small OOC signals do not result in OSS product. A process is said to be "robust" if its performance is not significantly uninfluenced by variations in process inputs (e.g., raw material lot), process variables (e.g., press force and speed), and environmental variables (e.g., ambient temperature and humidity).


Figure 6: Boxplots showing tablet hardness for two tablet presses (X and Y).
Variance analysis. Another way to assess process stability is to study the variation in process performance that is caused by potential special-cause variation (e.g., tablet presses, raw-material lots, process operating teams). Analysis of variance (ANOVA) enables one to identify variables that can increase variation in tablet parameters and that may produce OOS product (see Figure 6).

The boxplot in Figure 6 shows the distribution of tablet hardness values for a batch of tablets produced by two different tablet presses (X and Y). Press X has a wider hardness distribution than Press Y, yet none of the hardness values are outside the hardness specification of 1–6 kp. With this data in mind, the process operators can determine whether to make process adjustments.

After statistical significance of a comparison (e.g., average of Tablet Press X versus average of Tablet Press Y) is established, the practical significance of the difference in average values must be considered. This assessment is frequently carried out by expressing the observed difference in average values as a percentage of the overall process average. Subject-matter expertise is used to evaluate the practical importance of the observed percent difference.

Nested analysis of variance is another form of ANOVA used to assess process stability. Nested ANOVA can estimate the portion of the total variation in the data attributed to various sources of variation. Typically, the larger the percent of the total variation attributed to a source of variation, the more important is the source of variation. Low amounts (< 30%) of long-term variation as determined by a nested ANOVA indicate a stable process.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here